Rytvel Biotech announces that they have received a grant of $1.4 million from the National Health and Medical Research Council of Australia to conduct a new pre-clinical study on an IL-1R inhibitor (Rytvela) for the prevention for perinatal inflammation-induced fetal injury. The grants Rytvela has received now total $5.8 million to date.
In collaboration with Drs. Sylvain Chemtob and David Olson, Australian researchers led by professor Jeffrey Keelan from the University of Western Australia, the University of Adelaide, and Monash University are further exploring the use of Rytvela in parallel studies involving mice, sheep, spiny mice, and human placentas in laboratories across Australia.
“The insidious problem of preterm birth is that its inflammatory causes can also retard fetal organ development creating a doubly-vulnerable newborn baby prone to life-long morbidities”, says professor David Olson, department of obstetrics at the University of Alberta. “Australian investigators are among the world’s best at understanding the effects of inflammatory processes on fetal organ development. Using very rigorous methodologies in four different species, including human placenta, with a variety of inflammatory stimuli, this project will exhaustively further test the potential of Rytvela to block the effects of fetal inflammation and restore normal organogenesis in the fetus and thereby improve newborn health.”
Exposure to inflammation before or during birth is the major cause of increased risk of preterm birth and several serious perinatal and developmental complications affecting the fetal and newborn brain, lung, heart, and gut. There is no current in utero treatments to mitigate these effects. Rytvela will be used to block or ameliorate the effects of antenatal inflammation to improve perinatal and postnatal outcomes.
“After grants received from The Bill and Melinda Gates Foundation, the Canadian Institutes of Health Research, the Consortium Québécois sur la découverte du medicament, le Fonds de Recherche du Québec – Santé, March of Dimes, the Natural Sciences and Engineering Research Council of Canada, and the National Natural Science Foundation of China, this is the eighth major grant received for Rytvela,” says Jean-Paul Castaigne, MD, MBA, co-founder and CEO of Rytvel Biotech. “This clearly demonstrates the huge interest of the community for Rytvela.”
Thus far, Rytvela has demonstrated that it is an efficient and first-in-class drug for the prevention and treatment of preterm birth and any issues that have arisen thereafter.